Myriad Genetics CCO exit leaves 573K-share stake
Former Chief Commercial Officer Brian J. Donnelly exits Section 16 status while retaining substantial MYGN equity holdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MYRIAD GENETICS INC (MYGN) disclosed an "Exit" Form 4 for Brian J. Donnelly, who, effective September 16, 2026, no longer serves as Chief Commercial Officer and is therefore no longer subject to Section 16 reporting. The filing reports Donnelly’s continuing direct holdings of common stock and performance-based restricted stock units, but no new transactions or trades. No Rule 10b5-1 plan is reported.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Donnelly Brian J
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Performance-Based Restricted Stock Units F1 | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Holdings:
Performance-Based Restricted Stock Units — 236,167 contracts (Direct);
Common Stock — 573,363 shares (Direct)
Footnotes (1)
- F1. The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones.
Key Figures
Common Stock holdings: 573,363 shares
Maximum PSU underlying shares: 236,167 shares
PSU vesting tranches: 4 milestones, 25% per milestone
+1 more
4 metrics
Common Stock holdings
573,363 shares
Direct MYGN common stock held by Brian J. Donnelly after the reported change
Maximum PSU underlying shares
236,167 shares
Maximum MYGN shares that may vest under performance-based restricted stock units
PSU vesting tranches
4 milestones, 25% per milestone
PSUs vest upon achievement of four stock price milestones and committee certification
Officer exit date
September 16, 2026
Date Brian J. Donnelly ceased serving as Chief Commercial Officer and Section 16 status ended
Key Terms
Performance-Based Restricted Stock Units, stock price milestones, Section 16 reporting, Compensation and Human Capital Committee
4 terms
Performance-Based Restricted Stock Units financial
"The shares subject to the performance-based restricted stock units ("PSUs") represent"
Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.
stock price milestones financial
"may vest based on the Issuer's achievement of specified stock price milestones"
Section 16 reporting regulatory
"therefore is no longer subject to Section 16 reporting"
Compensation and Human Capital Committee regulatory
"will vest upon certification by the Compensation and Human Capital Committee"
A compensation and human capital committee is a board-level group that sets and oversees executive pay, employee incentive plans, hiring and retention strategies, succession planning, and workplace policies. Think of it as the company’s talent and pay steering team — it shapes who gets hired or promoted, how employees are rewarded, and how workforce risks are managed. Investors care because those choices drive labor costs, company performance, leadership stability and reputation, all of which affect long-term value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change does this Form 4 report for MYGN’s Brian J. Donnelly?
It reports that, effective September 16, 2026, Brian J. Donnelly no longer serves as Chief Commercial Officer of Myriad Genetics and therefore is no longer subject to Section 16 reporting. The filing is characterized as an "Exit" Form 4 and does not report new trades.
Does this MYGN Form 4 disclose any stock purchases or sales by Brian J. Donnelly?
No. The Form 4 indicates no reported purchases or sales. It only shows Donnelly’s holdings in common stock and performance-based restricted stock units as of his exit from Section 16 status.
What performance-based restricted stock units does Brian J. Donnelly hold in MYGN?
He holds performance-based restricted stock units tied to up to 236,167 underlying shares of Common Stock. These represent the maximum shares that may vest based on the company’s achievement of specified stock price milestones and related committee certification.
How do Brian J. Donnelly’s MYGN PSUs vest according to this Form 4?
The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, for a maximum of 236,167 shares that may vest.
Is a Rule 10b5-1 trading plan involved in this MYGN Form 4?
No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the disclosed holdings and status change.
AI-generated analysis. How Rhea-AI works. Not financial advice.
